|
|
Article: SEATTLE-AREA COMPANIES TRY TO DELIVER ON PROMISE OF RNAI TARGETED GENETICS PLANS CLINICAL TRIALS IN '09.(Business)
- Article from:
- Seattle Post-Intelligencer
- Article date:
- April 8, 2008
- Author:
CopyrightCOPYRIGHT 2008 Seattle Post-Intelligencer. All rights reserved. Reproduced with the permission of the Dialog Corporation by Gale Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: JOSEPH TARTAKOFF P-I reporter
In Huntington's disease, which afflicts about one in 10,000 Americans, one gene is defective - making it difficult for patients to walk, talk or swallow.
So, if there was a way to "silence" that one gene there could potentially be a cure.
That's the promise of RNA interference technology, and it has three Seattle-area companies trying to find a way to make it deliver.
"There has been no other technology that has been capable of shutting off aberrant genes," said H. Stewart Parker, the chief executive of Seattle-based Targeted Genetics.
On Monday, her company said it would accelerate its ...